Please assess the completion status of the following clinical trial:

Trial Title: Effects of Low Concentration Atropine on Pupillary Size and Accommodative Amplitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Able to read and comprehend Vietnamese and having parents or legal guardians who give informed consent as demonstrated by signing a record of informed consent.~* Be between 6 and 12 years old, male or female.~* Willing to apply eye drops once nightly at bedtime for two weeks and follow the clinical trial visit schedule as directed by the Investigator.~* Willing to answer the questionnaire about subjective measurements~* Have ocular findings deemed to be normal~* No contact lens wearing history~* Vision correctable to at least 20/25 or better in each eye with spectacles~Exclusion Criteria:~* Any pre-existing ocular irritation, injury or condition, including infection or disease.~* Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.~* Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.~* Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial.~NB: Systemic antihistamines are allowed on an as needed basis, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.~* History of eye surgery~* History of use of any myopia control interventions such as Orthokeratology, Rigid Permeable Contact Lenses Eye surgery within 12 weeks immediately prior to enrolment for this trial.~* Currently treated with other interventions for myopia control~* Contraindications to atropine such as pulmonary disease, heart conditions and ADHD~* Known allergy or intolerance to ingredients to atropine eye-drops and other derivatives of anti-muscarinic receptor agents.~* Currently enrolled in another clinical trial.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 0.01% atropine eye drops (Type: ACTIVE_COMPARATOR): Participants will receive one drop per eye every night for two weeks
- 0.02% atropine eye drops (Type: ACTIVE_COMPARATOR): Participants will receive one drop per eye every night for two weeks
- 0.03% atropine eye drops (Type: ACTIVE_COMPARATOR): Participants will receive one drop per eye every night for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).